Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, Perronne C, Carrat F; Agence Nationale pour la Recherche contre le SIDA et les Hépatites Virales HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: morand p. J Acquir Immune Defic Syndr. 2007 May 1;45(1):123-5. doi: 10.1097/QAI.0b013e318040b2b6. J Acquir Immune Defic Syndr. 2007. PMID: 17460476 No abstract available.
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C; ANRS Hc02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: morand p. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. doi: 10.1097/01.qai.0000174649.51084.46. J Acquir Immune Defic Syndr. 2005. PMID: 16123681
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Bani-Sadr F, Goderel I, Lapidus N, Driss H, Simon A, Rosenthal E, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, Perronne C, Carrat F; ANRS HC02 - RIBAVIC Study Team. Bani-Sadr F, et al. Among authors: morand p. AIDS. 2008 Jul 11;22(11):1385-7. doi: 10.1097/QAD.0b013e328305bd8d. AIDS. 2008. PMID: 18580626 Free article. Clinical Trial. No abstract available.
Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F, Bonarek M, Colin de Verdiere N, Pialoux G, Cacoub P, Pol S, Perronne C; ANRS HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: morand p. Clin Infect Dis. 2005 Dec 15;41(12):1806-9. doi: 10.1086/498312. Epub 2005 Nov 11. Clin Infect Dis. 2005. PMID: 16288408 Clinical Trial.
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team. Carrat F, et al. Among authors: morand p. JAMA. 2004 Dec 15;292(23):2839-48. doi: 10.1001/jama.292.23.2839. JAMA. 2004. PMID: 15598915 Clinical Trial.
Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A, Payan C, Morand P, Fafi-Kremer S, Deshayes J, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F. Pivert A, et al. Among authors: morand p. J Clin Microbiol. 2006 Feb;44(2):417-22. doi: 10.1128/JCM.44.2.417-422.2006. J Clin Microbiol. 2006. PMID: 16455894 Free PMC article. Clinical Trial.
596 results